Whenever I hear about Internet of Things (IoT), I think of smart fridges that have been touted as...
We are excited to announce that Isocitrate Dehydrogenase 1(IDH1) has been selected as Clovertex’s Target of the Month for August. IDH1 mutations are a key driver in various cancers, particularly gliomas, and are the focus of groundbreaking new treatments such as VORANIGO® (vorasidenib), recently approved by the FDA.
This spotlight on IDH1 follows the significant news that Servier Pharmaceuticals has received FDA approval for VORANIGO, marking a major milestone as the first targeted therapy for Grade 2 IDH-mutant glioma. Gliomas are a challenging type of brain cancer, often diagnosed in younger adults, and until now, patients had limited treatment options post-surgery. VORANIGO, an inhibitor of both IDH1 and IDH2, offers glioma patients a chance to actively manage their disease with a convenient, once-daily pill.
The Protein Imager rendering displays the cryo-EM structure of isocitrate dehydrogenase (PDB entry 5K10).
About Clovertex
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
Useful links
1. FDA approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
2. Clovertex website
